UnitedHealth Group has undergone a significant leadership change with the unexpected resignation of Andrew Witty. In a surprising turn, former CEO Stephen Hemsley has taken the helm once again.
This shakeup occurs amidst a troubling period for the healthcare giant, particularly following the tragic shooting of Brian Thompson, CEO of its subsidiary UnitedHealthcare.
Witty, who had led the company since 2021, departed immediately citing “personal reasons.” His exit comes after a series of setbacks that resulted in a staggering loss of nearly $190 billion in market value, eroding investor confidence.
Stock prices for UnitedHealth have plummeted over 35% since the year’s start, including a drastic 22% drop in just one day last month.
Hemsley, in a statement, expressed optimism about the company’s potential for growth as it seeks improvements in healthcare services. He emphasized the aim to reach long-term growth targets of 13-16%.
During Hemsley’s previous role as CEO from 2006 to 2017, UnitedHealth evolved from a conventional insurer to a major healthcare conglomerate valued at $400 billion, integrating various healthcare services.
His return is viewed as a stabilizing move during turbulent times. The company is navigating heightened scrutiny from regulators, ongoing investigations by the Justice Department, and the repercussions of Thompson’s murder.
Luigi Mangione, 27, has been charged with federal offenses related to Thompson’s death and faces potential capital punishment.
Additionally, UnitedHealth announced the suspension of its revised revenue outlook for 2025, which had previously been published in April. The company has lowered its annual revenue guidance to a range of $26 to $26.50 per share.
No new projections have been shared regarding stock exchanges.
Witty had tried to reassure investors amid concerns raised during an April revenue call, but the Wall Street response was swift and negative, leading to a historic decline in stocks.
Following that, shares dropped another 17%, translating to a loss of roughly $70 billion in value.
In contrast, competitors like CVS Health and Humana have not faced similar pressures in Medicare advantage costs lately, leaving UnitedHealth feeling somewhat isolated.
Michele Hooper, the lead independent director, noted that Hemsley possesses a valuable mix of strategic insight and operational focus that will benefit the company, and expressed confidence in his leadership during this transition.
As the changes unfold, UnitedHealth is also facing a shareholder lawsuit. The suit accuses the company of not disclosing the financial implications of consumer backlash after Thompson’s murder.
Filed in Manhattan federal court, the class-action lawsuit alleges that UnitedHealth misled investors about the strategic shifts taken post-shooting, particularly in how these changes would impact profitability.
Following Thompson’s December shooting, the company is said to have quietly shifted from its previous aggressive claim denial practices without informing shareholders of the associated financial risks.
This internal pivot left the company vulnerable and led to significant sales drops after the reduction in its 2025 revenue forecast.
UnitedHealth has yet to provide any immediate comments on these developments.
